Latest articles and price-sensitive announcements with AI sentiment classification.
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy surfs the supportive wave to psychedelic drug approval appeared first on Stockhead.
Entropy Neurodynamics hopes that an expected FDA breakthrough drug approval for depression will pave the way for its own psychedelic ... Read More The post Biocurious: Entropy rides a supportive wave towards psychedelic drug approval appeared first on Stockhead.
Safety gatekeepers have cleared Entropy Neurodynamics to advance to the second cohort of its psilocin-assisted binge eating disorder study. ... Read More The post Ever so safely, Entropy can kick off second stage of groundbreaking binge eating trial appeared first on Stockhead.
Entropy Neurodynamics (ASX:ENP) Shares Slip Despite DSMB Safety Clearance — What Do Investors Need to Know? Kalkine
director_dealing announcement
other announcement
Phase 2a trial enrolled 12 patients who had failed multiple standard treatments. ... Read More The post Entropy Neurodynamics reports 75pc response rate in IBS trial appeared first on Stockhead.
other announcement
director_dealing announcement
other announcement
director_dealing announcement
other announcement
other announcement
other announcement
other announcement
director_dealing announcement
director_dealing announcement
other announcement
director_dealing announcement
other announcement
director_dealing announcement
other announcement
other announcement
other announcement
other announcement
other announcement
Stockhead
Google News
ASX
Small Caps